Monogram Announces 2008 Second Quarter Financi...(say with IHC FISH and CISH resultsobtain...),Health

Date:7/29/2008

say with IHC, FISH and CISH results obtained in central laboratories in more than one thousand patients, and we see a high degree of concordance between the best central laboratory tests and HERmark," said Michael Bates, M.D., Vice President of Clinical Research at Monogram. "However, even when compared to the best central laboratory measurements, HERmark identifies patients with high HER2 levels but who are HER2-negative by other assays, as well as some patients with low HER2 levels but who are judged positive by conventional assays. Comparisons with local laboratory IHC or FISH results suggest significantly larger numbers of discordant results. We believe the HERmark Assay measures HER2 total protein and homodimer levels very accurately and will help physicians to make treatment decisions with high confidence." Monogram expects that as many as 15-20% of patients determined by conventional technologies to be HER2-negative would be reclassified by HERmark.

VeraTag(TM) Oncology Platform

Recent significant developments for the VeraTag technology platform include:

-- Introduction to biopharmaceutical companies of the HER1 and HER3 Total Protein Assays for research use.

-- Issuance of three U.S. patents and one European patent covering the detection and profiling with VeraTag technology of protein complexes, including homodimers and heterodimers.

While the HERmark Breast Cancer Assay, which measures the expression of the HER2 protein and the HER2:HER2 homodimer, is the first product to be developed based on Monogram's proprietary VeraTag technology, Monogram has a growing portfolio of VeraTag assays that measure proteins, protein complexes and post-translational modifications such as phosphorylation, in FFPE tumor samples. In addition to the HER1, HER2 and HER3 total protein assays and the HER2:HER2 homodimer assay, Monogram has assays in advanced development for the measurement of:

-- heterodimers of HER1 and HER2 (HER1:HER2) <
'/>"/>

SOURCE Monogram Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference